ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.390,31
0,23%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lumos Pharma Inc (LUMO)

  7. Lumos Pharma Inc (LUMO) News

LUMO

Lumos Pharma (LUMO)

Lumos Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LUMO
DatumZeitQuelleÜberschriftSymbolFirma
07/06/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
07/06/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
07/06/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
07/06/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
07/06/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
07/06/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/06/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUMOLumos Pharma Inc
04/06/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
04/06/202415h00GlobeNewswire Inc.Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024NASDAQ:LUMOLumos Pharma Inc
20/05/202422h05GlobeNewswire Inc.Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024NASDAQ:LUMOLumos Pharma Inc
15/05/202415h57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUMOLumos Pharma Inc
14/05/202422h15GlobeNewswire Inc.Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsNASDAQ:LUMOLumos Pharma Inc
09/05/202420h51GlobeNewswire Inc.Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024NASDAQ:LUMOLumos Pharma Inc
18/04/202422h05GlobeNewswire Inc.Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsNASDAQ:LUMOLumos Pharma Inc
20/03/202413h00GlobeNewswire Inc.Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042NASDAQ:LUMOLumos Pharma Inc
07/03/202422h48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LUMOLumos Pharma Inc
07/03/202422h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUMOLumos Pharma Inc
07/03/202422h01GlobeNewswire Inc.Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateNASDAQ:LUMOLumos Pharma Inc
26/02/202415h00GlobeNewswire Inc.Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024NASDAQ:LUMOLumos Pharma Inc
07/02/202423h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
06/02/202422h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202423h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202423h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202423h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202423h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202423h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
05/02/202422h05GlobeNewswire Inc.Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceNASDAQ:LUMOLumos Pharma Inc
11/01/202401h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LUMOLumos Pharma Inc
04/01/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUMOLumos Pharma Inc
04/01/202422h05GlobeNewswire Inc.Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerNASDAQ:LUMOLumos Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LUMO

Kürzlich von Ihnen besucht

CCOM
US100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
EURGBP
Euro vs Sterling
NASDAQ
MSFT
Microsoft
TG
D7G
Nel ASA
FX
EURUSD
Euro vs US Dollar
NASDAQ
AAPL
Apple
TG
DTE
Deutsche Telekom
TG
RHM
Rheinmetall
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
AMEX
SPY
SPDR S&P 500
NASDAQ
NVDA
NVIDIA
NYSE
XOM
Exxon Mobil
USOTC
BASFY
BASF (QX)
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten